A case of squamous cell lung cancer treated with anamorelin in combination with a multidisciplinary collaborative approach for treating cancer cachexia.

Authors :: Oshima Y
Matsuura H
Sakurai Y
Hirai K
Tani E
Yoshimoto N
Minami K
Yamasaki F
Nishime M
Hirashima T
Source :: Respiratory medicine case reports [Respir Med Case Rep] 2022 Feb 17; Vol. 36, pp. 101609. Date of Electronic Publication: 2022 Feb 17 (Print Publication: 2022).
Publication Year :: 2022
Abstract: Anamorelin (ANA) is approved for treating cancer cachexia (CCX) in Japan. We report the case of a 69-year-old man with stage IVB squamous cell lung cancer complicated by CCX, having a 13.6% weight loss in 6 months. After chemotherapy was initiated, his weight was further reduced. Therefore, we started ANA combined with a treatment approach by a multidisciplinary collaboration, including nutritionists and physical therapists. After initiation of ANA, the body weight, appetite, psoas muscle index, and physical functions rapidly improved during chemotherapy. ANA administration combined with a multidisciplinary collaboration approach can be an effective supportive therapy against CCX during chemotherapy.<br />Competing Interests: T.H. received research funding as a primary investigator from 10.13039/501100013170Ono Pharmaceutical Co., Ltd. (Osaka, Japan). The other authors declare no conflict of interest.<br /> (© 2022 Published by Elsevier Ltd.)

Full Text Access

Tools